Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
SHH: 688621.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yujing Liu
- Employees
- 1,556
- Headquarters
- Beijing, China
- IPO year
- 2021
- Market cap
- CN¥6.4B
- Website
- https://www.sun-novo.com
Loading 688621…
Loading profile data…Frequently asked questions about 688621
What does Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) do?
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of chemical drugs and peptide drugs in China. The company offers small molecule chemical generic drugs; peptide products; and drugs for indications, such as impetigo, acne, renal anemia, chronic kidney disease dialysis patient...
Where does 688621.SS trade?
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) trades on the Shanghai Stock Exchange.
What sector is 688621.SS in?
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Beijing Sun-Novo Pharmaceutical Research Co., Ltd.?
Yujing Liu is the chief executive officer of Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS).
Where is Beijing Sun-Novo Pharmaceutical Research Co., Ltd. headquartered?
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is headquartered in China.
Does 688621.SS pay a dividend?
Yes — Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) paid a trailing twelve-month dividend of CNY 0.16 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 688621.SS go public?
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) completed its initial public offering in 2021.